Ketamine for the Treatment of Opioid Use Disorder and Depression

Summary

The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.

Timeline

Start

2020-12-17

Primary completion

2022-11-21

Completion

2022-11-21

Drugs

Indications